Objectif
A rational approach to focused adjuvant therapy is urgently needed in the management of patients suffering from the most common cancers; the ability to identify patients at high risk would enable most cost-effective use of the treatments available. This proposal assembles a collaborative effort from seven leading European cancer research laboratories to identify new prognostic marker sets based on a systematic exploration of tissue protease systems functionally involved in tumour progression. The partners will apply state of the art molecular biology to identify the most relevant novel proteases, before embarking upon their quantitative measurement in large collections of patient material. The clinical studies for assessment of prognostic significance will examine the prognostic significance of each marker and derive marker sets, which optimise prognostic power. Commercially attractive kits will be assembled for the new marker sets.
Champ scientifique
Appel à propositions
Data not availableRégime de financement
CSC - Cost-sharing contractsCoordinateur
2100 KOEPENHAGEN
Danemark